Urogenital disorders associated with oestrogen deficiency: the role of promestriene as topical oestrogen therapy

References

• Chakraborty TR, Gore AC. Aging-related changes in ovarian hormones, their receptors, and neuroendocrine function. Exp Biol Med 2004;229:977–987.
   Web of Science ®Google Scholar
• The Practice Committee of the American Society of Reproductive Medicine. Estrogen and progestogen therapy in postmenopausal women. Fertil Steril 2004;82(Suppl. 1):S70–S80.
   Google Scholar
• Barlow DH, Cardozo LD, Francis RM, Griffin M, Hart DM, Stephens E, Sturdee DW. Urogenital ageing and its effect on sexual health in older British women. Br J Obstet Gynaecol 1997;104:87–91.
   PubMedGoogle Scholar
• Pastore LM, Carter RA, Hulka BS, Wells E. Self-reported urogenital symptoms in postmenopausal women: Women's Health Initiative. Maturitas 2004;49:292–303.
   PubMed Web of Science ®Google Scholar
• Al-Baghdadi O, Ewies AAA. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview. Climacteric 2009;12:91–105.
   PubMed Web of Science ®Google Scholar
• Lobo RA, Bélisle S, Creasman WT, Sims JM, Frankel NR, Goodman NF, Hall JE, Ivey SL, Kingsberg Slanger R, et al Should symptomatic menopausal women be offered hormone therapy? MedGenMed 2006;8:40.
   PubMedGoogle Scholar
• Frank JE, Mistretta P, Will J. Diagnosis and treatment of female sexual dysfunction. Am Fam Physician 2008;77:635–642.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Nijland EA. Women's perspective of sexuality around the menopause: outcomes of a European telephone survey. Eur J Obstet Gynecol Reprod Biol 2008;137:10–16.
   PubMed Web of Science ®Google Scholar
• Kao A, Binik YM, Kapuscinski A, Khalifé S. Dyspareunia in postmenopausal women: a critical review. Pain Res Manage 2008;13:243–254.
   PubMed Web of Science ®Google Scholar
• Graziottin A, Rovei V. Sexual pain disorders. In: Tepper MS, Owens AF, editors. Sexual health. Chapter 11. Westport, CT: Greenwood Publishing Group; 2006. pp. 287–312.
   Google Scholar
• Dennerstein L, Alexander JL, Kotz K. The menopause and sexual functioning: a review of the population-based studies. Annu Rev Sex Res 2003;14:64–82.
   PubMedGoogle Scholar
• Nappi RE, Lachowsky M. Menopause and sexuality: prevalence of symptoms and impact on quality of life. Maturitas 2009;63:138–141.
   PubMed Web of Science ®Google Scholar
• Gebhardt J, Richard D, Barrett T. Expression of estrogen receptor isoforms alpha and beta messenger RNA in vaginal tissue of premenopausal and postmenopausal women. Am J Obstet Gynecol 2001;185:1325–1330.
   PubMed Web of Science ®Google Scholar
• Quinn SD, Domoney C. The effects of hormones on urinary incontinence in postmenopausal women. Climacteric 2009;12:106–113.
   PubMed Web of Science ®Google Scholar
• Thomas TM, Plymat KR, Blannin J, Meade TW. Prevalence of urinary incontinence. BMJ 1980;281:1243–1245.
   PubMed Web of Science ®Google Scholar
• Burger H, Archer D, Barlow D, Birkhäuser M, Calaf-Alsina J, Gambacciani M, Genazzani A, Hadji P, Iversen OE, Kuhl H, et al Practical recommendations for hormone replacement therapy in the peri- and postmenopause. Climacteric 2004;7:210–216.
   PubMed Web of Science ®Google Scholar
• Pines A, Sturdee DW, Birkhäuser M, de Villiers T, Naftolin F, Gompel A, Farmer R, Barlow D, Tan D, Maki P, on behalf of the International Menopause Society. HRT in the early menopause: scientific evidence and common perceptions. Climacteric 2008;11:267–272.
   PubMed Web of Science ®Google Scholar
• Schmidt JW, Wollner D, Curcio J, Riedlinger J, Kim LS. Hormone replacement therapy in menopausal women: past problems and future possibilities. Gynecol Endocrinol 2006;22:564–577.
   PubMed Web of Science ®Google Scholar
• Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006;18: CD001500.
   Google Scholar
• Johnston SL, Farrell SA, Bouchard C, Farrell SA, Beckerson LA, Comeau M, Johnston SL, Lefebvre G, Papaioannou A. The detection and management of vaginal atrophy. J Obstet Gynaecol Can 2004;26:503–515.
   PubMedGoogle Scholar
• Ganz PA, Greendale GA, Petersen L, Zibecchi L, Kahn B, Belin TR. Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. J Natl Cancer Inst 2000;92:1054–1064.
   PubMed Web of Science ®Google Scholar
• Trinkaus M, Chin S, Wolfman W, Simmons C, Clemons M. Should urogenital atrophy in breast cancer survivors be treated with topical estrogens? The Oncologist 2008;13:222–231.
   PubMed Web of Science ®Google Scholar
• Dew JE, Wren BG, Eden JA. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric 2003;6:45–52.
   PubMed Web of Science ®Google Scholar
• Thomas JT, Mignot A, Roger M, Guillaume M. Compared absorption of promestriene by vaginal and oral routes in postmenopausal women. Presented at the 9th International Congress of Endocrinology, 30 August–5 September, Nice, France.
   Google Scholar
• Wolff J-P, Cachelou R, Guéritée N. Absence of systemic hormonal effects in an oestradiol diether topically active on the vaginal mucosa. Maturitas 1982;4:239–246.
   PubMed Web of Science ®Google Scholar
• Pálácios SJ, Uribe L, Fernandez Villoria E. Local and systemic effects after the intravaginal administration of estrogens (Promestrien) in menopausal women. Presented at the XIth World Congress of Gynaecology and Obstetrics, 15–20 September, Berlin, Germany; 1985.
   Google Scholar
• Palacios Gil Antuňano S, Peralta J, Mújica I, Fernandez Villoria E. Assessing estradiol diether systemic effects in premenopausal and postmenopausal women. Presented at the 19th National Congress of Gynecology, 22–24 October, Oviedo, Spain; 1987.
   Google Scholar
• Wurch TA, Lumbroso M, Becker J-F. Mise en évidence de l'absense d'effet systémique du promestriène employé à doses élevées. Gynécologie 1988;39:101–103.
   Google Scholar
• Bonneton A, Dechaud H, Fleury MC, Colau JC, Pugeat M. Absence d'influence du promestriène administré par voie vaginale sur le taux circulant des hormones et des protéines hépatiques estrogénodépendantes de la femme ménopausée. Gynécologie 1992;43:45–48.
   Google Scholar
• Romanini C, Villani L, Pasqua M, Gaglione R, Fischetti C, Fornara CF. Traitement prolongé de la vaginite atrophique par promestriène. Résultats et tolérance. Gynécologie 1980;31:627–631.
   Google Scholar
• Vors J, Muller P. Trophicité vaginale et Colpotrophine. Méd Gén 1975; 1 November 1.
   Google Scholar
• Campana G, Di Francesco G. Sindrome climacteria: esperienze cliniche con il promestriene. Ann Ost Gin Med Perin 1976;97:189–198.
   Google Scholar
• Romanini C, Paparatti L, Finelli FG. Activités estrogéniques locales et systémiques de deux topiques vaginaux utilisés dans le traitement des atrophies ménopausiques. Méd Hyg 1986;44:1562–1568.
   Google Scholar
• Baudet J-H, Pichereau D, Daffos F, Marceau B, Eyraud J-P. Therapeutic tests of the application of colpotrophine cream in cases of episiotomy immediately after childbirth. Gazette Med France 1978;85:4941–4942.
   Google Scholar
• Sadoul G, Beuret T, Thomas Jl. Healing of the uterine cervix after laser treatment – comparison of course after application of promestriene. Gynécologie 1986;37:332–336.
   Google Scholar
• Tinelli A, Malvasi A, D'Anna L, Tinelli R, Perrone A, Tinelli FG. Presurgical promestriene therapy in postmenopausal women with stress urinary incontinence. Gynecol Endocrinol 2007;23:445–450.
   Web of Science ®Google Scholar